NDC 72934-4070

DEXAMETHASONE SODIUM PHOSPHATE 0.1% / FINASTERIDE 0.1% / MINOXIDIL 5% / TRETINOIN 0.025%

Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025%

DEXAMETHASONE SODIUM PHOSPHATE 0.1% / FINASTERIDE 0.1% / MINOXIDIL 5% / TRETINOIN 0.025% is a Topical Solution in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida. The primary component is Dexamethasone Sodium Phosphate; Finasteride; Minoxidil; Tretinoin.

Product ID72934-4070_88612151-53b3-b592-e053-2995a90a0025
NDC72934-4070
Product TypeHuman Prescription Drug
Proprietary NameDEXAMETHASONE SODIUM PHOSPHATE 0.1% / FINASTERIDE 0.1% / MINOXIDIL 5% / TRETINOIN 0.025%
Generic NameDexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025%
Dosage FormSolution
Route of AdministrationTOPICAL
Marketing Start Date2019-05-09
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida
Substance NameDEXAMETHASONE SODIUM PHOSPHATE; FINASTERIDE; MINOXIDIL; TRETINOIN
Active Ingredient Strength0 g/100g; g/100g; g/100g; g/100g
Pharm ClassesCorticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA],5-alpha Reductase Inhibitor [EPC],5-alpha Reductase Inhibitors [MoA],Arteriolar Vasodilation [PE],Arteriolar Vasodilator [EPC],Retinoid [EPC],Retinoids [CS]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-4070-8

60 g in 1 BOTTLE, GLASS (72934-4070-8)
Marketing Start Date2019-05-09
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-4070-8 [72934407008]

DEXAMETHASONE SODIUM PHOSPHATE 0.1% / FINASTERIDE 0.1% / MINOXIDIL 5% / TRETINOIN 0.025% SOLUTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-09

Drug Details

Active Ingredients

IngredientStrength
DEXAMETHASONE SODIUM PHOSPHATE.1 g/100g

Pharmacological Class

  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]
  • 5-alpha Reductase Inhibitor [EPC]
  • 5-alpha Reductase Inhibitors [MoA]
  • Arteriolar Vasodilation [PE]
  • Arteriolar Vasodilator [EPC]
  • Retinoid [EPC]
  • Retinoids [CS]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]
  • 5-alpha Reductase Inhibitor [EPC]
  • 5-alpha Reductase Inhibitors [MoA]
  • Arteriolar Vasodilation [PE]
  • Arteriolar Vasodilator [EPC]
  • Retinoid [EPC]
  • Retinoids [CS]

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.